These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28853987)

  • 1. Forced degradation of recombinant monoclonal antibodies: A practical guide.
    Nowak C; K Cheung J; M Dellatore S; Katiyar A; Bhat R; Sun J; Ponniah G; Neill A; Mason B; Beck A; Liu H
    MAbs; 2017; 9(8):1217-1230. PubMed ID: 28853987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.
    Yang X; Xu W; Dukleska S; Benchaar S; Mengisen S; Antochshuk V; Cheung J; Mann L; Babadjanova Z; Rowand J; Gunawan R; McCampbell A; Beaumont M; Meininger D; Richardson D; Ambrogelly A
    MAbs; 2013; 5(5):787-94. PubMed ID: 23883920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical comparability study of recombinant monoclonal antibody therapeutics.
    Ambrogelly A; Gozo S; Katiyar A; Dellatore S; Kune Y; Bhat R; Sun J; Li N; Wang D; Nowak C; Neill A; Ponniah G; King C; Mason B; Beck A; Liu H
    MAbs; 2018; 10(4):513-538. PubMed ID: 29513619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
    Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
    Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced degradation of therapeutic proteins.
    Hawe A; Wiggenhorn M; van de Weert M; Garbe JH; Mahler HC; Jiskoot W
    J Pharm Sci; 2012 Mar; 101(3):895-913. PubMed ID: 22083792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
    Tamizi E; Jouyban A
    Eur J Pharm Biopharm; 2016 Jan; 98():26-46. PubMed ID: 26542454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.
    Wakankar AA; Liu J; Vandervelde D; Wang YJ; Shire SJ; Borchardt RT
    J Pharm Sci; 2007 Jul; 96(7):1708-18. PubMed ID: 17238195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations.
    Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE
    J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forced degradation studies: current trends and future perspectives for protein-based therapeutics.
    Chan CP
    Expert Rev Proteomics; 2016 Jul; 13(7):651-8. PubMed ID: 27285431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality by Design risk assessments supporting approved antibody products.
    Kelley B
    MAbs; 2016; 8(8):1435-1436. PubMed ID: 27618387
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
    Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
    J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparability assessments of process and product changes made during development of two different monoclonal antibodies.
    Lubiniecki A; Volkin DB; Federici M; Bond MD; Nedved ML; Hendricks L; Mehndiratta P; Bruner M; Burman S; Dalmonte P; Kline J; Ni A; Panek ME; Pikounis B; Powers G; Vafa O; Siegel R
    Biologicals; 2011 Jan; 39(1):9-22. PubMed ID: 20888784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle.
    Haurum J; Bregenholt S
    IDrugs; 2005 May; 8(5):404-9. PubMed ID: 15883923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing.
    Trexler-Schmidt M; Sargis S; Chiu J; Sze-Khoo S; Mun M; Kao YH; Laird MW
    Biotechnol Bioeng; 2010 Jun; 106(3):452-61. PubMed ID: 20178122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of electrochemistry to pharmaceutical stability testing--comparison with in silico prediction and chemical forced degradation approaches.
    Torres S; Brown R; Szucs R; Hawkins JM; Zelesky T; Scrivens G; Pettman A; Taylor MR
    J Pharm Biomed Anal; 2015 Nov; 115():487-501. PubMed ID: 26299525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.